Navigation Links
Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
Date:8/5/2008

SAN DIEGO, Aug. 5 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the second quarter ended June 30, 2008.

Total revenues in the second quarter of 2008 were $2.6 million, compared to $4.8 million in the second quarter of 2007, and included $2.0 million in revenue under Arena's contract manufacturing agreement with Siegfried Ltd and $0.6 million in patent reimbursements from Arena's collaborations with Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc. Total revenues in the first half of 2008 were $5.3 million, compared to $9.7 million in the first half of 2007. Arena reported a net loss allocable to common stockholders in the second quarter of 2008 of $65.8 million, or $0.89 per share, and a net loss allocable to common stockholders in the first half of 2008 of $120.8 million, or $1.64 per share. This compares with a net loss allocable to common stockholders in the second quarter of 2007 of $39.1 million, or $0.64 per share, and a net loss allocable to common stockholders in the first half of 2007 of $71.5 million, or $1.18 per share.

"Our commitment to generating a robust lorcaserin NDA, as part of our larger plan for discovering and developing innovative therapies, is capital intensive. However, we believe this helps increase our opportunities for success and improve returns for investors that share our mission to develop the best innovative therapies," stated Jack Lief, Arena's President and Chief Executive Officer. "We are well-positioned to continue to build on our accomplishments and achieve key milestones, including results from our pivotal BLOOM obesity trial, results from our APD125 Phase 2b insomnia trial and the advancement of our pipeline as we explore
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
2. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
3. ThreeWire Expands Presence in the Pharmaceutical Arena
4. Arena Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
5. Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
6. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Arena Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results
8. Arena Pharmaceuticals to Report Fourth Quarter and Full Year 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, February 27, 2008
9. Arena Pharmaceuticals to Present at the BIO CEO & Investor Conference
10. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Second Generation Niacin Receptor Agonist Under Its Collaboration With Merck & Co., Inc.
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... CA (PRWEB) February 26, 2015 The ... online demonstration to support life extension technologies and awareness. ... UTC, Universal Coordinated Time, on March 21st 2015, in ... world. , Eric Schulke, Founder of MILE, says, ... act with urgency. The Movement for Indefinite Life Extension ...
(Date:2/26/2015)... The Pittcon 2015 Exposition, which takes ... Morial Convention Center in New Orleans, Louisiana, will ... 2015) displaying products and services used by the ... The Exposition will offer the latest innovations in ... chemistry; drug discovery; nanotechnology; life sciences to include ...
(Date:2/26/2015)... Fla. , Feb. 26, 2015  Dyadic ... company whose patented and proprietary technologies are used ... proteins for the bioenergy, bio-based chemical, biopharmaceutical and ... report its financial results for year ending December ... 11, 2015 and will host a conference call ...
(Date:2/26/2015)... , Feb. 26, 2015   Lexicon Pharmaceuticals, Inc. ... management will present at the Cowen 35 th Annual ... a.m. EST in Boston .  Lexicon management ... milestones. A webcast of the presentation will be ... version of the presentation will be available at www.lexpharma.com ...
Breaking Biology Technology:Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3Pittcon 2015 Announces Exposition Highlights 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3Lexicon To Present At The Cowen 35th Annual Health Care Conference 2
... Inc. (Nasdaq: SEPR ), FRAMINGHAM, Mass. ... HTW) today announced that,veteran healthcare executive Timothy J. ... non- executive director, effective immediately., Barberich, 60, ... and chairman of Marlborough, MA-based Sepracor Inc., a ...
... ALEHT), a drug and diagnostic discovery company, announces,changes ... shareholders, meeting of the Company, that was,held on ... appointment as,member of the Supervisory Board, and as ... the age limit defined in the Company by-laws. ...
... EMERYVILLE, Calif., April 29 Onyx,Pharmaceuticals, Inc. (Nasdaq: ... with management to discuss first quarter 2008 financial,results and ... 2008, at,5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). ... will be released earlier that day., Interested parties ...
Cached Biology Technology:HeartWare Appoints Timothy J. Barberich to Board of Directors 2Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics 2Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics 3
(Date:2/24/2015)... Feb. 24, 2015 Research and Markets ... of the "Global 2D Gesture Recognition Market ... The analysts forecast the Global 2D Gesture ... 32.12% over the period 2014-2019 The ... sectors is one of the major trends in ...
(Date:2/12/2015)... Minn. , Feb. 12, 2015   ... company specializing in clinical study management systems, has ... Program , further distinguishing iMedNet ... Clinical Research Organizations (CROs) and healthcare consultants.  Building ... support, prospective customer referrals and numerous co-marketing opportunities), ...
(Date:2/5/2015)... , 5. Februar 2015 Marken ... Logistikunternehmen und hat eine neue Marketingkampagne gestartet, ... (Clinical Logistics Organization – CLO) der Branche ... lautet First , mit Schwerpunkt auf ... http://photos.prnewswire.com/prnh/20150205/173753 Logo - ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Marken startet Kampagne mit Patienten im Mittelpunkt 2Marken startet Kampagne mit Patienten im Mittelpunkt 3
... neurodegenerative disorder in which both genetic and environmental ... epigenetic changes (those molecular modifications that alter the ... Because accurate diagnosis is not easy for this ... signs of the disease that enable treatment before ...
... , Sept. 25, 2013 A technology-driven ... inter-agency collaboration, effective communication, and better use of ... include integrated communications and technology, multi-agency collaboration, shared ... A safe city will offer a developed environment, ...
... and his wife, Harriet Heyman, in collaboration with UC San ... million contribution to ensure the future of PhD education programs in ... recognition of the critical role doctoral students play in fueling ... in the history of the University of California. , ...
Cached Biology News:Frost & Sullivan: Safe Cities to directly impact First Responder and Biometric markets positively 2Frost & Sullivan: Safe Cities to directly impact First Responder and Biometric markets positively 3Frost & Sullivan: Safe Cities to directly impact First Responder and Biometric markets positively 4Frost & Sullivan: Safe Cities to directly impact First Responder and Biometric markets positively 5UCSF establishes largest endowed program for Ph.D. education in history of UC 2UCSF establishes largest endowed program for Ph.D. education in history of UC 3
Rabbit polyclonal to Shigella Immunogen: Mixture of S. boydii, S. flexneri & S. dysenteriae....
... The GSTTag Monoclonal Antibody is a ... affinity to the 26 kDa glutathione-S-transferase ... This purified antibody is suitable for ... sequence expressed in E. coli , ...
... miRCURY Array LNA microarray slides for ... microarray slides incorporate Exiqons unique Locked Nucleic ... and excellent mismatch discrimination for short microRNA ... less than 1 g total RNA (no ...
... Although there have been many modifications to ... defined media, salt solutions still play an important ... to maintain the pH and osmotic balance in ... water and essential inorganic ions, is as valuable ...
Biology Products: